| Abstrakt: |
Researchers at Qingdao Municipal Hospital in China have developed a new bi-single-atom nanoplatform, Zn/Cu-BSAN-DOX NPs, to reverse doxorubicin (DOX) resistance in breast cancer. This nanoplatform induces damage to mitochondria and breaks down barriers through reactive oxygen species (ROS) amplification, effectively reversing drug resistance. The study highlights the potential of this nanoplatform for multimodal therapy in drug-resistant breast cancer, emphasizing its role as a 'hexagonal' anti-tumor warrior. The research was funded by various organizations and has been peer-reviewed, offering new insights into innovative cancer therapies. [Extracted from the article] |
